Clinical Trials of Quadrivalent Influenza Vaccine

NCT06824519

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Enrollment	620 participants

Key Eligibility Criteria

Inclusion (4)

- When signing the informed consent form, be at least 18 years old and provide valid identification;
- The subject is able to understand the procedures and methods of this clinical trial, has given sufficient informed consent, voluntarily participated, and signed an informed consent form by the subject themselves;
- On the day of enrollment, axillary temperature was d 37.0 ;
- Female and male participants of childbearing age: agree to take effective contraceptive measures within 6 months after vaccination.

Exclusion (19)

- The laboratory test indicators specified in the protocol are abnormal and clinically significant before vaccination (only for Phase I);
- Have contracted influenza within the past 6 months prior to enrollment (confirmed by any clinical or microbiological method);
- Previously or currently suffering from autoimmune or immunodeficiency diseases;
- Previous history of severe allergies to any vaccine/drug or any component of the experimental vaccine, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, respiratory distress, angioneurotic edema, or individuals with an allergic constitution (such as allergies to two or more drugs, food, or pollen); History of severe allergy to eggs or egg protein;
- Have received any influenza vaccine within the 6 months prior to enrollment, or plan to receive influenza vaccine other than the vaccine used in this trial during the trial period (before completing the immunization and collecting blood samples);

... and 14 more (see full listing online)

Locations (1 total)

Hebei Province Centers for Disease Control and Prevention, Shijiazhuang, Hebei, China